Lorlatinib

Lorlatinib is a prescription medication used for the treatment of non-small cell lung cancer (NSCLC) that has spread to other parts of the body and has progressed after previous treatments, including crizotinib and alectinib. It is specifically indicated for patients whose cancer is positive for an abnormal ALK gene mutation.
Lorlatinib is an oral targeted therapy that works by inhibiting the activity of the ALK gene, which is responsible for driving the growth and spread of cancer cells. By blocking the ALK gene, lorlatinib prevents the uncontrolled cell division and helps slow down the progression of the disease.
The recommended dosage of lorlatinib is 100 mg taken once daily, with or without food. Follow the prescribed dosing schedule and not to exceed the recommended dose. Lorlatinib can cause side effects, including elevated liver enzymes, vision changes, constipation, swelling of the hands and feet, and increased heart rate. Patients should inform their healthcare provider if they experience any of these or other bothersome side effects.
Before starting treatment with lorlatinib, inform the healthcare provider about any medical conditions, allergies, or medications being taken, as these factors may affect the safety and efficacy of the treatment. Pregnant or breastfeeding women should also discuss the risks and benefits of lorlatinib with their healthcare provider, as it may not be suitable for them.